THERAKOS CELLEX Photopheresis Procedural Kit, CLXUSA
Mallinckrodt Pharmaceuticals Ireland Ltd began a recall of THERAKOS CELLEX Photopheresis Procedural Kit, CLXUSA on . FDA classified it as Class II and gives the reason as "This recall was initiated to recover a Dunnage Case, which is a case of three (3) CLXUSA kits. This Dunnage Case was shipped on 02-Dec-2021. Dunnage is used during the sterilization process and is not intended for...". As of , the recall status on record is Open, Classified, and MDM tags the root cause as sterility.
Recall record
- Recall number
- Z-0567-2022
- Classification
- Class II
- Status
- Open, Classified
- Initiated
- Posted
- Recalling firm
- Mallinckrodt Pharmaceuticals Ireland Ltd
- Product
- THERAKOS CELLEX Photopheresis Procedural Kit, CLXUSA
- Product code
- LNR System, Photopheresis, Extracorporeal
- Reason for recall
- This recall was initiated to recover a Dunnage Case, which is a case of three (3) CLXUSA kits. This Dunnage Case was shipped on 02-Dec-2021. Dunnage is used during the sterilization process and is not intended for customer use.
- Root cause tag
- sterility
- FDA root cause
- Under Investigation by firm
- Action
- On December 10, 2021, the firm initiated phone calls to potentially affected customers. The firm identified the location of the Dunnage Case on the same day, and the Dunnage Case was returned to the recalling firm.
- Quantity in commerce
- 3
- Distribution
- US Nationwide distribution in the states of CA, FL, GA, MA, MI, NC, NJ, NY, OH, TN, TX, VA, WV.
- Product codes and lots
- Dunnage case consists of a random unknown lot, which may have been shipped in place of Kit lot K341
Enforcement reports
One row per recalled product line| Recall number | Class | Status | Voluntary or mandated | Report date | Classified |
|---|---|---|---|---|---|
| Z-0567-2022 | Class II | Ongoing | Voluntary: Firm initiated |
FIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
